Atypical haemolytic uraemic syndrome

被引:97
作者
Kavanagh, David
Goodship, Timothy H. J.
Richards, Anna
机构
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
关键词
atypical haemolytic uraemic syndrome (aHUS); complement factor H (CFH); membrane cofactor protein (MCP; CD46); factor I (IF); renal transplantation; thrombotic thrombocytopenic purpura (TTP);
D O I
10.1093/bmb/ldl004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The haemolytic uraemic syndrome (HUS) is characterized by the triad of thrombocytopenia, microangiopathic haemolytic anaemia and acute renal failure. HUS may be classified as either diarrhoeal-associated or non-diarrhoeal/atypical (aHUS). aHUS has recently been shown to be a disease of complement dysregulation, with 50% of cases involving the complement regulatory genes, factor H (CFH), membrane cofactor protein (MCP; CD46), and factor I (IF). However, incomplete penetrance of mutations in each of these genes is reported. This suggests that a precipitating event or trigger is required to unmask the complement regulatory deficiency. The reported precipitating events predominantly cause endothelial injury. Discovery of these mutations has revealed important genotype-phenotype correlations. MCP-HUS has a better prognosis and a better outcome after transplantation than either CFH-HUS or IF-HUS.
引用
收藏
页码:5 / 22
页数:18
相关论文
共 59 条
[1]   Hemolytic uremic syndrome - An example of insufficient complement regulation on self-tissue [J].
Atkinson, JP ;
Liszewski, MK ;
Richards, A ;
Kavanagh, D ;
Moulton, EA .
NATURAL PRODUCTS AND MOLECULAR THERAPY, 2005, 1056 :144-152
[2]   HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: An observational study [J].
Becker, S ;
Fusco, G ;
Fusco, J ;
Balu, R ;
Gangjee, S ;
Brennan, C ;
Feinberg, J .
CLINICAL INFECTIOUS DISEASES, 2004, 39 :S267-S275
[3]   Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: Evidence of endothelin and cytokine involvement [J].
Burke, GW ;
Ciancio, G ;
Cirocco, R ;
Markou, M ;
Olson, L ;
Contreras, N ;
Roth, D ;
Esquenazi, V ;
Tzakis, A ;
Miller, J .
TRANSPLANTATION, 1999, 68 (09) :1336-1342
[4]   Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease [J].
Caprioli, J ;
Castelletti, F ;
Bucchioni, S ;
Bettinaglio, P ;
Bresin, E ;
Pianetti, G ;
Gamba, S ;
Brioschi, S ;
Daina, E ;
Remuzzi, G ;
Noris, M .
HUMAN MOLECULAR GENETICS, 2003, 12 (24) :3385-3395
[5]  
Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
[6]  
CAPRIOLI J, 2006, BLOOD
[7]  
CATTELL V, 1985, AM J PATHOL, V121, P88
[8]   Attempted treatment of factor H deficiency by liver transplantation [J].
Cheong, HI ;
Lee, BS ;
Kang, HG ;
Hahn, H ;
Suh, KS ;
Ha, IS ;
Choi, Y .
PEDIATRIC NEPHROLOGY, 2004, 19 (04) :454-458
[9]   Non-enteropathic hemolytic uremic syndrome: Causes and short-term course [J].
Constantinescu, AR ;
Bitzan, M ;
Weiss, LS ;
Christen, E ;
Kaplan, BS ;
Cnaan, A ;
Trachtman, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (06) :976-982
[10]   High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome [J].
Coppo, P ;
Bussel, A ;
Charrier, S ;
Adrie, C ;
Galicier, L ;
Boulanger, E ;
Veyradier, A ;
Leblanc, T ;
Alberti, C ;
Azoulay, E ;
Le Gall, JR ;
Schlemmer, B .
MEDICINE, 2003, 82 (01) :27-38